Stomach cancer

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer [internet publication].Full text

Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005-20.Full text  Abstract

Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010 May;11(5):439-49. Abstract

Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Abstract

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.Full text  Abstract

Bang YJ, Van CE, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Abstract

1. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49. Abstract

2. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part 1. Clinical classification. Jpn J Surg. 1981 Mar;11(2):127-39. Abstract

3. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993 Nov;218(5):583-92. Abstract

4. World Health Organization. Global Cancer Observatory: cancer fact sheets, stomach cancer. Dec 2022 [internet publication].Full text

5. American Cancer Society. Cancer facts & figures 2024. 2024 [internet publication].Full text

6. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49.Full text  Abstract

7. Turati F, Tramacere I, La Vecchia C, et al. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013 Mar;24(3):609-17.Full text  Abstract

8. Wu B, Yang D, Yang S, et al. Dietary salt intake and gastric cancer risk: a systematic review and meta-analysis. Front Nutr. 2021 Dec 8;8:801228.Full text  Abstract

9. Shibata A, Parsonnet J, Longacre TA, et al. CagA status of Helicobacter pylori infection and p53 mutations in gastric adenocarcinoma. Carcinogenesis. 2002 Mar;23(3):419-24. Abstract

10. Eslick GD, Lim LL, Byles JE, et al. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999 Sep;94(9):2373-9. Abstract

11. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol. 2007;21(2):281-97. Abstract

12. Nam SY, Park BJ, Nam JH, et al. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development. Gastrointest Endosc. 2019 Sep;90(3):448-56.e1. Abstract

13. Zheng L, Wang L, Ajani J, et al. Molecular basis of gastric cancer development and progression. Gastric Cancer. 2004;7(2):61-77. Abstract

14. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014 Sep 11;513(7517):202-9.Full text  Abstract

15. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer: a population-based cohort study. Cancer. 1993 Feb 1;71(3):745-50. Abstract

16. You WC, Zhang L, Yang CS, et al. Nitrite, N-nitroso compounds, and other analytes in physiological fluids in relation to precancerous gastric lesions. Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):47-52. Abstract

17. D'Elia L, Galletti F, Strazzullo P. Dietary salt intake and risk of gastric cancer. Cancer Treat Res. 2014;159:83-95. Abstract

18. Wu X, Chen L, Cheng J, et al. Effect of dietary salt intake on risk of gastric cancer: a systematic review and meta-analysis of case-control studies. Nutrients. 2022 Oct 12;14(20):4260.Full text  Abstract

19. Morais S, Costa A, Albuquerque G, et al. Salt intake and gastric cancer: a pooled analysis within the Stomach cancer Pooling (StoP) Project. Cancer Causes Control. 2022 May;33(5):779-91.Full text  Abstract

20. Tredaniel J, Boffetta A, Buiatti E, et al. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer. 1997 Aug 7;72(4):565-73. Abstract

21. Fitzgerald RC, Caldos C. Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. Gut. 2004 Jun;53(6):775-8. Abstract

22. Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open. 2018 Jul 7;8(7):e021869.Full text  Abstract

23. Ford AC, Yuan Y, Forman D, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020 Jul 6;(7):CD005583.Full text  Abstract

24. Bosetti C, Santucci C, Gallus S, et al. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. 2020 May;31(5):558-68.Full text  Abstract

25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer [internet publication].Full text

26. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005-20.Full text  Abstract

27. Seko-Nitta A, Nagatani Y, Murakami Y, et al. 18F-fluorodeoxyglucose uptake in advanced gastric cancer correlates with histopathological subtypes and volume of tumor stroma. Eur J Radiol. 2021 Dec;145:110048. Abstract

28. Kim HW, Won KS, Song BI, et al. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging. 2015 Jun;49(2):135-42.Full text  Abstract

29. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006 Jan 21;12(3):354-62. Abstract

30. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005 Nov;129(5):1753-5.Full text  Abstract

31. Tracey JP, Traube M. Difficulties in the diagnosis of pseudoachalasia. Am J Gastroenterol. 1994 Nov;89(11):2014-8. Abstract

32. Amin MB, Greene FL, Edge SB, et al. AJCC (American Joint Committee on Cancer) cancer staging manual. 8th ed. New York, NY: Springer; 2017:xvii;1024.

33. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999 Aug;230(2):170-8. Abstract

34. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg. 1989 Feb;209(2):162-6. Abstract

35. ASGE standards of practice committee, Forbes N, Elhanafi SE, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. Gastrointest Endosc. 2023 Sep;98(3):271-84.Full text  Abstract

36. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004276.Full text  Abstract

37. Takekoshi T, Baba Y, Ota H, et al. Endoscopic resection of early gastric carcinoma; results of a retrospective analysis of 308 cases. Endoscopy. 1994 May;26(4):352-8. Abstract

38. Soetikno R, Kaltenbach T, Yeh R, et al. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol. 2005 Jul 10;23(20):4490-8. Abstract

39. Cushieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996 Apr 13;347(9007):995-9. Abstract

40. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010 May;11(5):439-49. Abstract

41. Sasako M, Sano T, Yamamoto S, et al; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008 Jul 31;359(5):453-62.Full text  Abstract

42. Ohtani H, Tamamori Y, Noguchi K, et al. A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg. 2010 Jun;14(6):958-64. Abstract

43. Kim W, Kim HH, Han SU, et al; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. Abstract

44. Kim HH, Han SU, Kim MC, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: the KLASS-01 randomized clinical trial. JAMA Oncol. 2019 Apr 1;5(4):506-13.Full text  Abstract

45. Best LM, Mughal M, Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2016 Mar 31;(3):CD011389.Full text  Abstract

46. Dikken JL, Jansen EP, Cats A, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol. 2010 May 10;28(14):2430-6.Full text  Abstract

47. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30.Full text  Abstract

48. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Abstract

49. Park SH, Lim DH, Sohn TS, et al; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021 Mar;32(3):368-74.Full text  Abstract

50. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20;27(6):851-6.Full text  Abstract

51. Moertel CG, Childs DS, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy for locally advanced and metastatic gastric carcinoma. Lancet. 1969 Oct 25;2(7626):865-7. Abstract

52. Le Chevalier T, Smith FP, Harter WK, et al. Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. Semin Oncol. 1985 Mar;12(1):46-53. Abstract

53. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.Full text  Abstract

54. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009 Jan;96(1):26-33. Abstract

55. ClinicalTrials.gov. 5-FU, leucovorin, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric cancer. NCT01216644. Jun 2019 [internet publication].Full text

56. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 Feb;8(2):163-8. Abstract

57. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017 Aug 29;(8):CD004064.Full text  Abstract

58. Pyrhönen S, Kuitunen T. Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587-91. Abstract

59. Bang YJ, Van CE, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Abstract

60. ClinicalTrials.gov. Efficacy study of nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy in stomach cancer or stomach/esophagus junction cancer (CheckMate649). NCT02872116. Jun 2021 [internet publication].Full text

61. Kelly RJ, Ajani JA, Kuzdzal J, et al; CheckMate 577 Investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021 Apr 1;384(13):1191-203.Full text  Abstract

62. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-40.Full text  Abstract

63. Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):234-47. Abstract

64. National Institute for Health and Care Excellence. Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma​. Jan 2023 [internet publication].Full text

65. Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023 Mar 1;41(7):1470-91.Full text  Abstract

66. Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-95. Abstract

67. Cunningham D, Rao S, Starling T, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol. Abstract LBA4017. Paper presented at: 2006 ASCO Annual Meeting. 2006 Jun 20;24(18 Suppl):LBA4017.Full text

68. Al-Batran S, Hartmann JT, Probst S, et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). Abstract LBA4016. Paper presented at: 2006 ASCO Annual Meeting. J Clin Oncol. 2006 Jun 20;24(18 Suppl):LBA4016.Full text

69. Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011 Mar;14(1):50-5. Abstract

70. Wilke H, Muro K, Van Cutsem E, et al; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. Abstract

71. Fuchs CS, Tomasek J, Yong CJ, et al; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Abstract

72. Shitara K, Bang YJ, Iwasa S, et al; DESTINY-Gastric01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020 Jun 18;382(25):2419-30.Full text  Abstract

73. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. Abstract

74. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Abstract

75. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Oct 21;19(11):1437-48. Abstract

76. National Institute for Health and Care Excellence. Trifluridine-tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. Jan 2022 [internet publication].Full text

77. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-65. Abstract

78. Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: a combined analysis of two cohorts in the GARNET study. Abstract 2564. Paper presented at: 2021 ASCO Annual Meeting. J Clin Oncol. 2021 May 20;39(15_Suppl):2564.Full text

79. Boku N, Yamamoto S, Fukuda H, et al; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Abstract

80. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. Abstract

81. Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019 May 20;37(15):1296-304.Full text  Abstract

82. Zhang X, Liang H, Li Z, et al; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-92. Abstract

83. Wainberg ZA, Kang YK, Lee KW, et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024 May;27(3):558-70.Full text  Abstract

84. ClinicalTrials.gov. Bemarituzumab plus chemotherapy and nivolumab versus chemotherapy and nivolumab for FGFR2b overexpressed untreated advanced gastric and gastroesophageal junction cancer. (FORTITUDE-102). ClinicalTrials.gov Identifier: NCT05111626. Sep 2024 [internet publication].Full text

85. ClinicalTrials.gov. Bemarituzumab or placebo plus chemotherapy in gastric cancers with fibroblast growth factor receptor 2b (FGFR2b) overexpression (FORTITUDE-101). ClinicalTrials.gov Identifier: NCT05052801. Jun 2024 [internet publication].Full text

86. Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial. J Clin Oncol. 2016 Aug 10;34(23):2728-35.Full text  Abstract

87. Martin AJ, Gibbs E, Sjoquist K, et al. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. Gastric Cancer. 2018 May;21(3):473-80.Full text  Abstract

88. ClinicalTrials.gov. A study of regorafenib in refractory advanced gastro-oesophageal cancer (INTEGRATEIIa). NCT02773524. Jan 2022 [internet publication].Full text

89. Lam LL, Pavlakis N, Shitara K, et al. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer. 2023 Feb 22;23(1):180.Full text  Abstract

90. ClinicalTrials.gov. RegoNivo vs standard of care chemotherapy in AGOC (INTEGRATEIIb). ClinicalTrials.gov Identifier: NCT04879368. May 2024 [internet publication].Full text

91. Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Apr;17(10):1155-64.Full text  Abstract

92. ClinicalTrials.gov. Combination margetuximab, retifanlimab, tebotelimab, and chemotherapy phase 2/3 trial in HER2+ gastric/GEJ Cancer (MAHOGANY). NCT04082364. Apr 2022 [internet publication].Full text

93. Lakhani NJ, Chow LQM, Gainor JF, et al. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-51. Abstract

94. ClinicalTrials.gov. A study of evorpacept (ALX148) in patients with advanced HER2+ gastric cancer (ASPEN-06). NCT05002127. Apr 2022 [internet publication].Full text

95. ClinicalTrials.gov. Study of TJ033721 in subjects with advanced or metastatic solid tumors. NCT04900818. Apr 2022 [internet publication].Full text

96. Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020 Feb;158(3):693-702.Full text  Abstract

97. Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017 Feb;35(4):446-64.Full text  Abstract

98. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023 Jan;26(1):1-25.Full text  Abstract

99. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: stomach cancer. 2023 [internet publication].Full text

100. Yao JC, Crane CC, Mansfield PF. Carcinoma of the stomach. In: Kufe DW, Bast R, Hait W, et al, eds. Cancer medicine. 7th ed. Hamilton, Ontario: BC Decker; 2006:1268-91.

101. Kasakura Y, Ajani JA, Mochizuki F, et al. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. J Surg Oncol. 2002 Aug;80(4):181-5. Abstract

102. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81.Full text  Abstract

103. Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020 Jul 20;38(21):2438-53.Full text  Abstract

104. Roeland EJ, Bohlke K, Baracos VE, et al. Cancer cachexia: ASCO guideline rapid recommendation update. J Clin Oncol. 2023 Sep 1;41(25):4178-9.Full text  Abstract

105. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Abstract

106. NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication].Full text

107. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.

108. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. Abstract

109. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. Abstract